BMS-202 explained

BMS-202 is a small-molecule drug PD-L1 inhibitor developed by Bristol-Myers Squibb which displays significant anti-tumor activity against glioblastoma (GBM) cells.[1] In addition, BMS-202 has an inhibitory effect on both PD-L1-expressing cancer cells and activated T cells.[2]

Notes and References

  1. Immunity, Inflammation and Disease . BMS-202, a PD-1/PD-L1 inhibitor, decelerates the pro‑fibrotic effects of fibroblasts derived from scar tissues via ERK and TGFβ1/Smad signaling pathways . 2022 . 10.1002/iid3.693 . 10 . 10 . e693 . 36169254 . 9449589 . Cai Y, Xiao M, Li X, Zhou S, Sun Y, Yu W, Zhao T .
  2. Biomedical Research . Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse . 2019 . 10.2220/biomedres.40.243 . 40 . 6 . 243–250 . 31839668 . Ashizawa T, Iizuka A, Tanaka E, Kondou R, Miyata H, Maeda C, Sugino T, Yamaguchi K, Ando T, Ishikawa Y, Ito M, Akiyama Y . free .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "BMS-202".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2025, A B Cryer, All Rights Reserved. Cookie policy.